No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Implantica AG, a medical technology firm established in 2015 and based in Vaduz, Liechtenstein, specializes in the research, development, and commercialization of advanced medical implants. The company focuses on addressing critical, unmet medical needs, primarily conducting its operations and sales in Switzerland. Its flagship offering is RefluxStop, a CE-marked, passive implant designed for the effective prevention of gastroesophageal reflux disease. Implantica is also actively developing a range of other innovative solutions, including e-InVivo, an internal sensor implant capable of monitoring a wide array of health parameters, providing diagnostic data, and facilitating in-body treatment control. The company is also developing a proprietary wireless energizing platform, which serves as a foundation for several remote-controlled devices. These include AppetiteControl, an implant designed to manage obesity by regulating appetite; UriControl, a remote-activated implant for treating urinary incontinence in both men and women; and UriRestor, a remote-controlled device leveraging the wireless platform to enable individuals with spinal cord injuries and multiple sclerosis to urinate on demand. Implantica AG operates as a subsidiary of Implantica MediSwiss.
www.implantica.comNo one on the platform currently holds IMP-A-SDB.ST.
No tracked institution reports a position in IMP-A-SDB.ST as of their last filing.
No one on the platform has traded IMP-A-SDB.ST yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | +53.6% | $-0.31 | $-0.31–$-0.31 | — | 1 |
| 2027 | $9M | +200.0% | $-0.38 | $-0.38–$-0.38 | — | 1 |
| 2028 | $27M | +188.9% | $-0.34 | $-0.34–$-0.34 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-21 | $-0.80 | $-0.67 | +16.3% |
| 2026-05-22 | $-0.89 | $-0.68 | +24.1% |
| 2026-02-25 | $-1.09 | $-1.09 | +0.0% |
| 2025-10-31 | $-0.86 | $-0.66 | +23.1% |
| 2025-08-14 | $-1.29 | $-0.90 | +30.7% |
| 2025-05-09 | $-1.26 | $-0.11 | +91.6% |
| 2025-02-14 | $-1.04 | $-1.04 | +0.0% |
| 2024-11-15 | $-1.22 | $-1.02 | +16.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| IMP-A-SDB.STImplantica AG | $60.90 | -0.16% | $3.6B | — |
| BICO.STBICO Group AB (publ) | $20.80 | +1.71% | $1.4B | — |
| CEVI.STCellaVision AB (publ) | $159.60 | -0.87% | $3.8B | — |
| EGTX.STEgetis Therapeutics AB (publ) | $7.88 | +0.13% | $3.7B | — |
| FLERIE.STFlerie AB (publ) | $17.90 |
| +1.13% |
| $1.6B |
| — |
| HNSA.STHansa Biopharma AB (publ) | $38.18 | +0.95% | $3.8B | — |
| HUM.STHumana AB (publ) | $69.00 | +1.77% | $3.3B | — |
Source: Financial Modeling Prep · peers by sector/industry